LOGC LogicBio Therapeutics Inc.

8.28
+0.42  (+5%)
Previous Close 7.86
Open 8.1
52 Week Low 3.05
52 Week High 14
Market Cap $194,030,158
Shares 23,433,594
Float 12,734,348
Enterprise Value $141,035,048
Volume 107,428
Av. Daily Volume 65,356
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
LB-001 - SUNRISE
Methylmalonic Acidemia (MMA)
Phase 1/2
Phase 1/2
Phase 1/2 enrollment to commence early 2021.

Latest News

  1. – LogicBio's First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform

    Enrollment to Start with Patients as Young as 3 Years Old, De-escalating Down to 6 Months old –

    – Webcast and Conference Call Today at 8 a.m. ET to Discuss LB-001 Update –

    LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the clinical trial design for the planned Phase 1/2 clinical trial for LB-001 in pediatric patients with methylmalonic acidemia (MMA) .

    "We're pleased to announce our plans for developing LB-001 in pediatric…

    – LogicBio's First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform

    Enrollment to Start with Patients as Young as 3 Years Old, De-escalating Down to 6 Months old –

    – Webcast and Conference Call Today at 8 a.m. ET to Discuss LB-001 Update –

    LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the clinical trial design for the planned Phase 1/2 clinical trial for LB-001 in pediatric patients with methylmalonic acidemia (MMA) .

    "We're pleased to announce our plans for developing LB-001 in pediatric patients with MMA. This is an important milestone for patients, their families, our company and for the genetic medicines space more broadly as we believe this is the first Investigational New Drug application (IND) clearance for an in vivo gene editing program harnessing homologous recombination," said Fred Chereau, CEO of LogicBio. "We have maintained a steadfast commitment to execution and the IND clearance is the first of several near-term milestones we expect to reach in our determined efforts to leverage cutting-edge medicines to address high unmet medical needs. I look forward to sharing those updates as we advance our LB-001 program."

    Daniel Gruskin, M.D., SVP, head of clinical development, commented, "The effects of MMA usually appear shortly after birth and can quickly become severe and life-threatening. Early intervention in this vulnerable population is critical to combat the manifestation of irreversible clinical disease pathologies including neurological damage. That's the reason MMA is on the newborn screening panel in the United States. Our protocol allows for the first cohort to enroll patients as young as three years old and, once certain safety parameters are met, we can age de-escalate to as young as six months old. Our goal is to provide a safe and durable therapeutic with a single administration at an age when we can make a difference for these patients."

    SUNRISE - Phase 1/2 Clinical Trial of LB-001 in Pediatric Methylmalonic Acidemia (MMA)

    The SUNRISE trial is a multi-center, open-label, Phase 1/2 clinical trial designed to assess the safety and tolerability of a single intravenous infusion of LB-001 in pediatric patients with MMA characterized by methylmalonyl-CoA mutase gene (MMUT) mutations. Six leading centers in the United States are expected to participate in the SUNRISE Phase 1/2 trial. The trial is expected to enroll eight pediatric patients with ages ranging from 6 months to 12 years, initially starting with 3 to 12 year-old patients and then adding patients aged 6 months to 2 years. The SUNRISE Phase 1/2 trial will evaluate two doses of LB-001. Patients will participate in a pre-dosing observational period and will be administered a prophylactic steroid regimen. The primary endpoint of the SUNRISE trial is to assess the safety and tolerability of LB-001 at 52 weeks after a single infusion. Additional endpoints include changes in disease-related biomarkers, including serum methylmalonic acid, clinical outcomes such as growth and healthcare utilization, and the pharmacodynamic marker albumin-2A. The Company expects to enroll the first patient in early 2021.

    LB-001 Webcast and Conference Call Information

    LogicBio will host a webcast and conference call on Monday, August 10, 2020 at 8:00 a.m. ET. The webcast will feature an overview of recently generated preclinical data using LB-001 and the planned clinical development plan for LB-001.

    The event will be broadcast live and available under the investor relations section of LogicBio's website at https://investor.logicbio.com/. The dial-in details for the call are +1 833-519-1335 or +1 602-585-9978, Conference ID: 1151546. A replay of the webcast will be available on the LogicBio website for one month following the call.

    About LogicBio Therapeutics

    LogicBio Therapeutics is dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms.

    LogicBio's proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio has received FDA clearance for the first-in-human clinical trial of LB-001, a wholly owned genome editing program leveraging GeneRide for the treatment of methylmalonic acidemia. Patient enrollment is expected to begin in early 2021. In addition, LogicBio has a collaboration with Takeda to research and develop LB-301, an investigational therapy leveraging GeneRide for the treatment of the rare pediatric disease Crigler-Najjar syndrome.

    LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies. Data presented have shown that the capsids deliver highly efficient functional transduction of human hepatocytes with improved manufacturability with low levels of pre-existing neutralizing antibodies in human samples. Top-tier capsid candidates from this effort demonstrated significant improvements over benchmark AAVs currently in clinical development. LogicBio is developing these highly potent vectors for internal development candidates and potentially for business development collaborations.

    LogicBio is headquartered in Lexington, Mass. For more information, please visit www.logicbio.com.

    Forward Looking Statements

    This press release contains "forward-looking" statements within the meaning of the federal securities laws, including those related to the Company's plans to initiate, advance and complete its planned SUNRISE Phase 1/2 clinical trial of LB-001 in MMA; the timing, progress and results of the Company's research and development activities, including those related to the GeneRide technology platform and Next Generation Capsid Program; and its plans for LB-301 in Crigler-Najjar. These are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available. They are subject to risks and uncertainties that could cause the actual results and the implementation of the Company's plans to vary materially, including the risks associated with the initiation, cost, timing, progress and results of the Company's current and future research and development activities and preclinical studies and potential future clinical trials. In particular, the impact of the COVID-19 pandemic on the Company's ability to progress with its research, development, manufacturing and regulatory efforts, including the Company's plans to initiate, advance and complete its Phase 1/2 clinical trial for LB-001 in MMA, and the value of and market for the Company's common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. These risks are discussed in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including, without limitation, the Company's Annual Report on Form 10-K filed on March 16, 2020 with the SEC, the Company's Quarterly Report on Form 10-Q filed on May 11, 2020, and the Company's subsequent Quarterly Reports on Form 10-Q and other filings with the SEC. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

    Contacts:

    Investors:

    Brian Luque

    Associate Director, Investor Relations



    951-206-1200

    Media:

    Stephanie Simon

    Ten Bridge Communications



    617-581-9333

    Primary Logo

    View Full Article Hide Full Article
  2. LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today reported financial results for the quarter ended June 30, 2020, provided a business update and announced the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for LB-001 for the treatment of methylmalonic acidemia in pediatric patients. LogicBio released a separate press release this morning providing further details on the planned Phase 1/2 clinical design for LB-001.

    "We are thrilled to have received clearance to move forward with this first-in-human…

    LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today reported financial results for the quarter ended June 30, 2020, provided a business update and announced the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for LB-001 for the treatment of methylmalonic acidemia in pediatric patients. LogicBio released a separate press release this morning providing further details on the planned Phase 1/2 clinical design for LB-001.

    "We are thrilled to have received clearance to move forward with this first-in-human clinical trial with our lead product candidate, LB-001, for the treatment of methylmalonic acidemia, a life-threatening congenital genetic disease with no current therapeutic treatment options. This represents a significant milestone in our goal of bringing a treatment to MMA patients as well as for our GeneRide platform. We have maintained continuous dialogue with the centers of excellence that are planned to participate in the Phase 1/2 clinical trial, and we look forward to activating these sites as quickly as possible," said Fred Chereau, CEO of LogicBio. "We have instituted systems attempting to mitigate COVID-19 dynamics on our study start-up process and, based on our best estimates, we plan to enroll our first patient in early 2021."

    Commenting on the Next Generation Capsid Program, Mr. Chereau said, "We are very excited about the recent advances in our novel capsid program, which has generated liver-tropic capsids intended for use in gene editing technologies such as GeneRide and other gene therapy approaches. We are focused on executing across all of our programs and look forward to sharing further details on our novel capsids in early 2021."

    Appointment of Daniel Gruskin, M.D. to SVP, Head of Clinical Development

    Daniel Gruskin, M.D. was appointed as SVP, head of clinical development in August 2020. Dr. Gruskin has served as interim head of clinical development of LogicBio since June 2020. In April 2020, Dr. Gruskin started consulting with the Company as a special advisor. Previously, Dr. Gruskin served in roles of increasing responsibility at Sanofi Genzyme, most recently as vice president, head of global medical affairs, rare disease, in which capacity he oversaw medical affairs, life cycle management, scientific affairs and other medical and development activities related to metabolic, rare and/or genetic diseases. Prior to his role at Sanofi Genzyme, Dr. Gruskin served as assistant professor, human genetics and pediatrics at Emory University School of Medicine, where he was also the chief of the genetics section at Children's Healthcare of Atlanta.

    "Daniel has been instrumental in leading LB-001 clinical development efforts including getting the IND cleared. His deep experience in genetic medicines and metabolic diseases will serve LogicBio well as we look to execute on our goals for both the GeneRide and Next Generation Capsid platforms in search of transformative medicines," said Mr. Chereau.

    Anticipated Milestones for 2020 and 2021:

    • GeneRide Platform
      • LB-001 for MMA
        • Early 2021: First patient enrollment in Phase 1/2 trial
      • Platform
        • Early 2021: Translational model data
    • Next Gen Capsid Platform
      • Early 2021:  Translational model data

    Second Quarter 2020 Financial Results

    Three Months Ended June 30, 2020 and 2019

    • R&D Expenses: Research and development expenses for the three months ended June 30, 2020 were $5.9 million, compared to $7.9 million for three months ended June 30, 2019. The decrease was primarily due to decreases of approximately $2.3 million in external development and manufacturing expenses for the Company's lead product candidate, LB-001, and a decrease of $0.1 million in personnel-related costs as increased headcount was offset by salary cuts related to the COVID-19 pandemic. These decreases were partially offset by an increase of $0.3 million in other research and development expenses as the Company increased its overall research and development activities related to general platform development. While there may be fluctuations on a quarterly basis, the Company expects that its research and development costs will decrease during 2020 as compared to 2019 as it has already incurred a significant proportion of the LB-001 external development and manufacturing costs needed to bring LB-001 into clinical development.
    • G&A Expenses: General and administrative expenses were $3.0 million for the three months ended June 30, 2020, compared to $2.5 million for the three months ended June 30, 2019. The increase was primarily due to increases in corporate legal expense, D&O insurance premiums and non-capitalizable facilities expenses. The Company expects that general and administrative expenses will remain relatively consistent during 2020 as compared to 2019 although there may be fluctuations on a quarterly basis.
    • Net Loss: Net loss was $8.2 million, or $0.35 per share, for the three months ended June 30, 2020, compared to a net loss of $10.0 million, or $0.45 per share, for the three months ended June 30, 2019.
    • Cash Position and Financial Guidance: Cash and cash equivalents were $36.7 million as of June 30, 2020.  The Company believes that its cash and cash equivalents as of June 30, 2020 will enable the Company to fund operating expenses and capital expenditure requirements into the third quarter of 2021.

    About LogicBio Therapeutics

    LogicBio Therapeutics is dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms.

    LogicBio's proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio has received FDA clearance for the first-in-human clinical trial of LB-001, a wholly owned genome editing program leveraging GeneRide for the treatment of methylmalonic acidemia. Patient enrollment is expected to begin in early 2021. In addition, LogicBio has a collaboration with Takeda to research and develop LB-301, an investigational therapy leveraging GeneRide for the treatment of the rare pediatric disease Crigler-Najjar syndrome.

    LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies. Data presented have shown that the capsids deliver highly efficient functional transduction of human hepatocytes with improved manufacturability with low levels of pre-existing neutralizing antibodies in human samples. Top-tier capsid candidates from this effort demonstrated significant improvements over benchmark AAVs currently in clinical development. LogicBio is developing these highly potent vectors for internal development candidates and potentially for business development collaborations.

    LogicBio is headquartered in Lexington, Mass. For more information, please visit www.logicbio.com.

    Forward Looking Statements

    This press release contains "forward-looking" statements within the meaning of the federal securities laws, including those related to the Company's plans to initiate, advance and complete its planned SUNRISE Phase 1/2 clinical trial of LB-001 in MMA; the timing, progress and results of the Company's research and development activities, including those related to the GeneRide technology platform and Next Generation Capsid Program; its plans for LB-301 in Crigler-Najjar; and the sufficiency of its cash and cash equivalents to fund operating expenses and capital expenditure requirements. These are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available. They are subject to risks and uncertainties that could cause the actual results and the implementation of the Company's plans to vary materially, including the risks associated with the initiation, cost, timing, progress and results of the Company's current and future research and development activities and preclinical studies and potential future clinical trials. In particular, the impact of the COVID-19 pandemic on the Company's ability to progress with its research, development, manufacturing and regulatory efforts, including the Company's plans to initiate, advance and complete its Phase 1/2 clinical trial for LB-001 in MMA, and the value of and market for the Company's common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. These risks are discussed in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including, without limitation, the Company's Annual Report on Form 10-K filed on March 16, 2020 with the SEC, the Company's Quarterly Report on Form 10-Q filed on May 11, 2020, and the Company's subsequent Quarterly Reports on Form 10-Q and other filings with the SEC. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.



    LogicBio Therapeutics, Inc.
    Condensed Consolidated Statements of Operations
    (In thousands, except share and per share data)
    (Unaudited)
            
     Three Months Ended June 30, Six Months Ended June 30,
      2020   2019   2020   2019 
    REVENUE       
    Service revenue$965  $  $1,986  $ 
    Total revenue 965      1,986    
    OPERATING EXPENSES       
    Research and development 5,895   7,934   13,068  $13,420 
    General and administrative 3,029   2,524   6,221   5,156 
    Total operating expenses 8,924   10,458   19,289   18,576 
    LOSS FROM OPERATIONS (7,959)  (10,458)  (17,303)  (18,576)
    OTHER INCOME (EXPENSE), NET:       
    Interest income 10   411   177   854 
    Interest expense (273)     (545)   
    Other expense, net (5)  (1)  (11)  (1)
    Total other (expense) income, net (268)  410   (379)  853 
    Loss before income taxes (8,227)  (10,048)  (17,682)  (17,723)
    Income tax provision          (22)
    Net loss$(8,227) $(10,048) $(17,682) $(17,745)
    Net loss per share—basic and diluted$(0.35) $(0.45) $(0.76) $(0.79)
    Weighted-average common stock outstanding—basic and diluted 23,326,018   22,479,511   23,250,910   22,396,780 
            



    LogicBio Therapeutics, Inc.
    Condensed Consolidated Balance Sheets
    (In thousands)
    (Unaudited)
     As of
     June 30, 2020  December 31, 2019
    Cash, cash equivalents and investments$36,697 $50,647
    Other assets 10,646  5,013
    TOTAL ASSETS$47,343 $55,660
        
    Accounts payable, accrued expenses and other liabilities$19,187 $13,373
    Stockholders' equity 28,156  42,287
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$47,343 $55,660
        

    Contacts:

    Investors:

    Brian Luque

    Associate Director, Investor Relations

     

    951-206-1200

    Media:

    Stephanie Simon

    Ten Bridge Communications



    617-581-9333

    Primary Logo

    View Full Article Hide Full Article
  3. LEXINGTON, Mass., June 05, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:  LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that its 2020 Annual Meeting of Stockholders (2020 Annual Meeting) will be held in a virtual-only format due to continued public health concerns related to coronavirus / COVID-19, and to support the health and well-being of our stockholders and other meeting participants. The previously announced date and time of the meeting, June 19, 2020, at 9:00 a.m. E.T., will not change.

    Stockholders will have the same rights and opportunities to participate in the virtual meeting as they would have at an…

    LEXINGTON, Mass., June 05, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:  LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that its 2020 Annual Meeting of Stockholders (2020 Annual Meeting) will be held in a virtual-only format due to continued public health concerns related to coronavirus / COVID-19, and to support the health and well-being of our stockholders and other meeting participants. The previously announced date and time of the meeting, June 19, 2020, at 9:00 a.m. E.T., will not change.

    Stockholders will have the same rights and opportunities to participate in the virtual meeting as they would have at an in-person meeting. To gain access to the meeting, stockholders must go to the meeting website at http://www.meetingcenter.io/273338066. The password for the meeting is LOGC2020. The virtual meeting website will contain additional details regarding participation in the 2020 Annual Meeting.

    Whether or not stockholders plan to virtually attend the 2020 Annual Meeting, LogicBio urges all stockholders to vote and submit their proxy in advance of the meeting by one of the methods described in the proxy materials for the 2020 Annual Meeting.  Stockholders who have previously voted do not need to take any further action.

    As described in the proxy statement for the 2020 Annual Meeting, stockholders are able to participate if:

    • They were registered stockholders as of the close of business on April 22, 2020, or
    • They hold a legal proxy for the 2020 Annual Meeting.

    Beneficial owners as of the record date (i.e., shares held in "street name" through an intermediary, such as a bank or broker) must register in advance to attend and vote at the 2020 Annual Meeting. To register, stockholders must obtain a legal proxy from the holder of record and submit proof of legal proxy reflecting the number of shares of LogicBio common stock held as of the record date, along with their name and email address, to Computershare at . Requests for registration must be labeled as "Legal Proxy" and must be received no later than Tuesday, June 16, 2020, 5:00 p.m. E.T. Stockholders will then receive a confirmation of registration with a control number by email from Computershare.

    To be admitted to the virtual 2020 Annual Meeting, stockholders will need to enter the 15-digit control number found on their proxy card (for registered stockholders) or the email confirmation of registration (for beneficial stockholders who properly registered in advance).

    Previously distributed proxy cards and voting instruction forms will not be updated to reflect the change from an in-person meeting to a virtual-only meeting and may continue to be used to vote shares in connection with the 2020 Annual Meeting.

    For further information, please refer to the Company's proxy statement and Notice Regarding the Availability of Proxy Materials, filed with the Securities and Exchange Commission on April 29, 2020, each of which can be accessed at investor.logicbio.com.

    Guests may participate in a listen-only mode. No control number is required.

    About LogicBio Therapeutics

    LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients with significant unmet medical needs using GeneRide™, its proprietary technology platform. GeneRide enables the site-specific integration of a therapeutic transgene in a nuclease-free and promoterless approach by relying on the native process of homologous recombination to drive potential lifelong expression. LogicBio is also developing the Next Generation Capsid Development Program for which data has been presented showing highly efficient functional transduction of human hepatocytes with improved manufacturability and enhanced resistance to pre-existing human neutralizing antibodies. Headquartered in Lexington, Mass., LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.

    For more information, please visit www.logicbio.com.

    Contacts:

    Brian Luque

    Associate Director, Investor Relations



    951-206-1200

    Primary Logo

    View Full Article Hide Full Article
  4. LEXINGTON, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 8:00 a.m. ET.

    A live audio webcast of the presentation will be available under the "Events and Presentations" section of LogicBio's website. A replay of the presentation will become available approximately one hour after the event and will be archived for 30 days.

    About LogicBio Therapeutics
    LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in pediatric…

    LEXINGTON, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 8:00 a.m. ET.

    A live audio webcast of the presentation will be available under the "Events and Presentations" section of LogicBio's website. A replay of the presentation will become available approximately one hour after the event and will be archived for 30 days.

    About LogicBio Therapeutics
    LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients with significant unmet medical needs using GeneRide™, its proprietary technology platform. GeneRide enables the site-specific integration of a therapeutic transgene in a nuclease-free and promoterless approach by relying on the native process of homologous recombination to drive potential lifelong expression. Headquartered in Lexington, Mass., LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.

    For more information, please visit www.logicbio.com.

    Contacts:

    Brian Luque
    Associate Director, Investor Relations

    951-206-1200

    Primary Logo

    View Full Article Hide Full Article
  5. LEXINGTON, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced upcoming presentations at the American Society of Gene & Cell Therapy (ASGCT) 2020 Annual Meeting, held virtually, May 12-15, 2020.

    "We continue to advance our understanding of the GeneRide™ platform and are especially pleased to be sharing encouraging preclinical data on a novel methylmalonic acidemia model at this year's virtual ASGCT meeting," said Fred Chereau, CEO of LogicBio. "Beyond GeneRide platform data, we will also be sharing data on the Next Generation Capsid Development Program demonstrating…

    LEXINGTON, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced upcoming presentations at the American Society of Gene & Cell Therapy (ASGCT) 2020 Annual Meeting, held virtually, May 12-15, 2020.

    "We continue to advance our understanding of the GeneRide™ platform and are especially pleased to be sharing encouraging preclinical data on a novel methylmalonic acidemia model at this year's virtual ASGCT meeting," said Fred Chereau, CEO of LogicBio. "Beyond GeneRide platform data, we will also be sharing data on the Next Generation Capsid Development Program demonstrating highly efficient functional transduction of human hepatocytes with improved manufacturability and enhanced resistance to pre-existing human neutralizing antibodies."

    Oral Presentation
    Title: Treatment of Juvenile Mice with Methylmalonic Acidemia (MMA) by Targeted Integration of MMUT into Albumin Using a Promoterless AAV Vector
    Presenter: Leah Venturoni, Ph.D., NHGRI NIH collaborator
    Session Title: Genome Editing in Inborn Errors of Metabolism
    Session Date/Time: Thursday May 14, 2020 3:45 p.m. - 5:30 p.m. EDT
    Presentation Time: 5:00 p.m. - 5:15 p.m. EDT
    Abstract Number: 963

    Poster Presentations
    Title: Durable and Efficacious Transgene Expression Driven by GeneRide in Liver Injury Models
    Session Title: Gene Targeting and Gene Correction
    Session Date/Time: Tuesday May 12, 2020 5:30 p.m. - 6:30 p.m. EDT
    Abstract Number: 208

    Title: Developing a Potency Assay for AAV-Based Genome Editing Vectors
    Session Title: Vector and Cell Engineering, Production or Manufacturing
    Session Date/Time: Tuesday May 12, 2020 5:30 p.m. - 6:30 p.m. EDT
    Abstract Number: 434

    Title: AAV Development Program: Towards the Next Generation of Human Livertropic AAV Variants
    Session Title: AAV Vectors - Virology and Vectorology
    Session Date/Time: Wednesday May 13, 2020 5:30 p.m. - 6:30 p.m. EDT
    Abstract Number: 564

    Title: Nuclease-Free Glucose-6-Phosphatase-α Gene Integration Ameliorates Hypoglycemia in Glycogen Storage Disease Type Ia
    Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases
    Session Date/Time: Wednesday May 13, 2020 5:30 p.m. - 6:30 p.m. EDT
    Abstract Number: 682

    Title: GeneRide-Encoding hUGT1A1 Rescues Phenotypes of a Mouse Model of Crigler-Najjar Syndrome
    Session Title: Gene Targeting and Gene Correction
    Session Date/Time: Thursday May 14, 2020 5:30 p.m. - 6:30 p.m. EDT
    Abstract Number: 1049

    Additional information on the meeting can be found on the ASGCT website: https://annualmeeting.asgct.org/am20/

    About LogicBio Therapeutics
    LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients with significant unmet medical needs using GeneRide™, its proprietary technology platform. GeneRide enables the site-specific integration of a therapeutic transgene in a nuclease-free and promoterless approach by relying on the native process of homologous recombination to drive potential lifelong expression. Headquartered in Lexington, Mass., LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.

    For more information, please visit www.logicbio.com.

    Forward Looking Statements

    This press release contains "forward-looking" statements within the meaning of the federal securities laws. These are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available. They are subject to risks and uncertainties that could cause the actual results and the implementation of the Company's plans to vary materially, including the risks associated with the initiation, cost, timing, progress and results of the Company's current and future research and development activities and preclinical studies and potential future clinical trials. These risks are discussed in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including, without limitation, the Company's Annual Report on Form 10-K filed on March 16, 2020 with the SEC, and the Company's subsequent Quarterly Reports on Form 10-Q and other filings with the SEC. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

    Contacts:

    Brian Luque
    Associate Director, Investor Relations

    951-206-1200

    Primary Logo

    View Full Article Hide Full Article
View All LogicBio Therapeutics Inc. News